FULC

In April 2026, Fulcrum Therapeutics reported positive clinical data from the Phase 1b PIONEER trial of pociredir in sickle cell disease, showing robust fetal hemoglobin (HbF) induction and improvements in markers of hemolysis and anemia. However, in June 2026, the stock plunged approximately 50% after the company announced the discontinuation of its pociredir program due to heightened FDA concerns regarding the drug's benefit-risk profile in SCD, citing malignancy risk associated with the PRC2 inhibitor class. This event led to a strategic review. In August 2026, Fulcrum Therapeutics announced an all-stock merger agreement with Slate Medicines, Inc., aiming to create a combined company focused on Slate's migraine therapies, with Fulcrum shareholders expected to own 5.0% of the combined entity, anticipated to close in Q4 2026. Overall, the company's share price declined by 49.53% between September 2025 and September 2026 and by 52.41% over the last six months.